Apimeds Pharmaceuticals US, Inc.
APUS
Closed
$0.74
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
Key stats
Open
$0.73
Volume
24.93K
Market cap
$11.09M
Prev. close
$0.73
Impl / hst vl
-
Open interest
$0.00
$0.73
Day’s Range
$0.74
$0.73
52W Range
$5.97
Valuation
33
Valuation score
Overvalued
P/E
-
P/S
-
P/B
0.09
Current ratio
0.90
Debt / Equity
0.07
ROE
-
Gross margin
-
Income growth
2,934.70%
FCF growth
-150.15
Analysts estimates
Earnings
Q1 ‘26 revenue
$0.00
Q1 ‘26 net income
-$35.06M
Revenue
Net income
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply